How do you manage persistent cytopenias in patients with AML who achieve a complete remission with incomplete count recovery after venetoclax and HMA?  

This is an important question. How to manage cytopenias on HMA + venetoclax-based regimens is one of the biggest conundrums in the management of AML. The clinical trials to date have not uniformly answered this question based on level 1 evidence. These recommendations are mainly based on anecdotal d...

This is a challenging and frequent question regarding the upfront use of venetoclax and hypomethylating agents in older individuals. Our practice is as outlined by @Joshua F. Zeidner, except that we perform a bone marrow biopsy on day 21 of first cycle of therapy. If there is evidence of cytoreducti...